INDIA MARKET LENS

Cipla Limited (CIPLA): research summary

Price history, fundamentals, business-quality scores, DCF intrinsic value, shareholding, quarterly results and risk metrics for Cipla Limited, explained in plain English.

  • Cipla Limited is tracked in the Pharma & Healthcare sector of the NSE universe covered here.
  • CIPLA closed at ₹1,417.00 on 18 November 2026.
  • Over the past year the shares are down 6.4%, trading between ₹1,165.70 and ₹1,539.70.
  • Reported fundamentals show return on equity of 8.33%, a net margin of 10.35%, debt to equity of 1.97.
  • Our Pulse grade checklist scores it D (48/100) across momentum, growth, profitability and safety, using Pharma & Healthcare sector medians as the bar.
  • Annualised volatility over the past year is 19.88% with a maximum drawdown of -22.13% and a beta of 0.51 against NIFTY 50.
  • Recent coverage: Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%

Other Pharma & Healthcare companies: Abbott India, Acutaas Chemicals, Ajanta Pharmaceuticals, Alkem Laboratories, Anthem Biosciences, Apollo Hospitals Enterprise, Aster DM Quality Care, Aurobindo Pharma

Last traded values from 18 Nov 2026. Market closed.

Cipla Limited (CIPLA)

₹1,417

▲ 29 (+2.09%)

Price & volume

CIPLA price chart, 1Y range. 252 points from 2025-11-21 to 2026-11-18. Opens at 1,511.8, closes at 1,417, ranging between 1,192.4 and 1,531.3.1,2001,3001,4001,500Nov-25Jan-26Mar-26May-26Jun-26Aug-26Sep-26Nov-26volume

Hover for exact price & volume · green/red volume bars show up vs down days

Strong momentum · 4/5
✓ Above 50-day avg✓ Above 200-day avgRSI 62.3 · healthyMACD positiveBollinger %B 80ADX 21.8 · weak trend

1M

+6.94%

3M

-0.99%

6M

-0.65%

1Y

-6.44%

Where it sits in its 52-week range

66%
₹1,192.4₹1,531.3

Below 52-week high

7.5%

18.8% above the low

Momentum read

Strong

4/5 checks passed

52-wk high

₹1,531.3

52-wk low

₹1,192.4

Market cap

₹1,14,478 Cr

P/E (trailing)

39.5

Dividend yield

—

ROE

8.33%

Profit margin

10.35%

Revenue growth

-1.1%

Price / Book

3.23

Debt / Equity

1.97

EPS (TTM)

35.84

Book value

₹438.13

Beta

0.51

Pulse grade: D, 48 out of 100

Momentum

B
  • ✓Trading above 50-day average
  • ✓Trading above 200-day average
  • ✓RSI in healthy 45-70 zone
  • ✕Positive 3-month return

Growth

D
  • ✕Revenue growth above Pharma & Healthcare median (20.8%)
  • ✕Revenue growing above 5%
  • ✓Quarterly profits trending up

Profitability

F
  • ✕Return on equity above Pharma & Healthcare median (14.64%)
  • ✕Return on equity above 12%
  • ✕Profit margin above Pharma & Healthcare median (13.82%)

Safety

A
  • ✓Debt below Pharma & Healthcare median (18.57)
  • ✓Debt not extreme for the sector
  • ✓Less volatile than the market (beta < 1.2)
  • ✕Pays a dividend

Quarterly revenue vs net profit

Revenue Net profit₹ crore, by quarter

Sep 2026: revenue ₹7,368 crore · net profit ₹878 crore · margin 11.9%

7,3680Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026

Business quality

Intrinsic value

Building the model…

Analyst coverage

Who owns this company

Events, dividends & splits

Market position

Pharma & Healthcare sector

PeerPrice ₹Day changeFrom 52-wk high
SUNPHARMA1,871.5+0.08%-6.48%
DRREDDY1,398.2+0.73%0.00%
DIVISLAB11,049-0.91%-4.47%
APOLLOHOSP8,821+1.25%-2.73%
LUPIN1,971.9+1.12%-21.59%
AUROPHARMA1,796.3+0.12%-3.18%

CIPLA headlines

No CIPLA stories right now.

CIPLA filings & announcements

Reading the exchange…

CIPLA, historical timeline

The timeline will be ready shortly

The rest of the page is unaffected.

Risk & return, last 12 months

Volatility (ann.)

19.88%

Sharpe ratio

-0.55

Sortino ratio

-0.84

Max drawdown

-22.13%

Daily VaR (95%)

-1.53%

CAGR (1Y)

-6.29%

Return skew

1.38

Sharpe/Sortino use a 7% risk-free rate. VaR-95 = the daily loss exceeded only 5% of days last year.

Risk profile over time

Quant tearsheet

Monthly returns, how deep the falls ran, and how tightly it tracks NIFTY.